• TG Therapeutics recently reported fourth-quarter 2025 results showing revenue of US$192.57 million, up sharply from US$108.19 million a year earlier, while quarterly net income was essentially flat and earnings per share came in below analyst expectations.
• For 2025 as a whole, the company recorded US$616.29 million in revenue and a very large increase in net income to US$447.18 million, largely reflecting the growing contribution of BRIUMVI alongside raised guidance for 2026.
• We’ll now examine how this earnings miss alongside higher 2026 BRIUMVI revenue guidance affects TG Therapeutics’ existing investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to believe that BRIUMVI can remain a leading MS therapy while the company successfully broadens its franchise with new formulations and indications. The Q4 earnings miss and softer EPS do not appear to alter the most immediate catalyst, which is progress on subcutaneous BRIUMVI, but they do highlight how dependent profitability is on a single product and on controlling costs in the near term.

The most relevant recent announcement here is TG’s raised 2026 BRIUMVI revenue guidance to US$875 million to US$900 million globally, despite the Q4 EPS shortfall and modest revenue miss versus expectations. That guidance, together with strong 2025 BRIUMVI sales, reinforces why upcoming ENHANCE and subcutaneous BRIUMVI data are central to the story, while also sharpening the risk if reimbursement pressure or competing MS therapies begin to slow that growth.

Yet beneath the strong 2025 numbers, one risk investors should be aware of is how rising payer pressure on MS drug pricing could...

TG Therapeutics' narrative projects $1.2 billion revenue and $469.0 million earnings by 2028.

Uncover how TG Therapeutics' forecasts yield a $44.43 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming TG’s revenue would be about US$1.0 billion and earnings around US$344.7 million by 2028, and this Q4 miss may reinforce that more pessimistic view for you compared with the more optimistic narrative that leans heavily on BRIUMVI’s continued commercial ramp and margin expansion.

Explore 7 other fair value estimates on TG Therapeutics - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.